| Identification | Back Directory | [Name]
BC2059 | [CAS]
1227637-23-1 | [Synonyms]
BC2059
Tegavivint
BC-2059;BC2059;TEGAVIVINT
TEGATRABETAN;BC-2059;TEGAVIVINT
9,10-Anthracenedione, 2,7-bis[[(3R,5S)-3,5-dimethyl-1-piperidinyl]sulfonyl]-, 9,10-dioxime, rel- | [Molecular Formula]
C28H36N4O6S2 | [MOL File]
1227637-23-1.mol | [Molecular Weight]
588.74 |
| Chemical Properties | Back Directory | [Boiling point ]
757.6±70.0 °C(Predicted) | [density ]
1.46±0.1 g/cm3(Predicted) | [storage temp. ]
Inert atmosphere,2-8°C | [solubility ]
DMSO: 125 mg/mL (212.32 mM) | [pka]
10.07±0.20(Predicted) |
| Hazard Information | Back Directory | [Biological Activity]
Tegatrabetan (BC2059) is a beta-Catenin antagonist. It disrupts β-catenin binding to scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and reduces β-catenin nuclear levels. | [in vivo]
Tegatrabetan (BC2059; 1.0 or 5.0 mg/kg/day; intravenously) significantly improves the median survival of the mice from approximately 17.5 to 39 days. Treatment with Tegatrabetan (10 mg/kg/day; intravenously) alone further improves the median survival to 51.5 days. | Animal Model: | NOD/SCID mice bearing OCI-AML3 xenografts | < /tr> | Dosage: | 1 mg/kg; 5 mg/kg; 10 mg/kg | | Administration: | Intravenously; 1 mg/kg daily 4 days per week or 5 mg/kg or 10 mg/kg of BC2059 twice per week (Tuesday and Thursday) for 3 weeks. | | Result: | Treatment significantly improved survival of NOD/SCID mice bearing OCI-AML3 xenografts. | | [target]
| [storage]
Store at -20°C |
|
| Company Name: |
DC Chemicals
|
| Tel: |
021-58447131 13564518121 |
| Website: |
https://www.chemicalbook.com/ShowSupplierProductsList927327/0.htm |
|